168 related articles for article (PubMed ID: 26914167)
1. A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma.
Smeland KB; Kiserud CE; Lauritzsen GF; Blystad AK; Fagerli UM; Falk RS; Fluge Ø; Fosså A; Kolstad A; Loge JH; Maisenhölder M; Østenstad B; Kvaløy S; Holte H
Br J Haematol; 2016 May; 173(3):432-43. PubMed ID: 26914167
[TBL] [Abstract][Full Text] [Related]
2. High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma: Data From the Japan Society for Hematopoietic Cell Transplantation Registry.
Kondo E; Ikeda T; Izutsu K; Chihara D; Shimizu-Koresawa R; Fujii N; Sakai T; Kondo T; Kubo K; Kato Y; Akasaka T; Fukuda T; Ichinohe T; Atsuta Y; Suzumiya J; Suzuki R;
Biol Blood Marrow Transplant; 2019 May; 25(5):899-905. PubMed ID: 30664936
[TBL] [Abstract][Full Text] [Related]
3. Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients.
Ruiz-Soto R; Sergent G; Gisselbrecht C; Larghero J; Ertault M; Hennequin C; Manson J; de Kerviler E; Briere J; Mounier N
Cancer; 2005 Dec; 104(12):2735-42. PubMed ID: 16284986
[TBL] [Abstract][Full Text] [Related]
4. Mortality patterns among recipients of autologous hematopoietic stem cell transplantation for lymphoma and myeloma in the past three decades.
Bhatt VR; Loberiza FR; Jing H; Bociek RG; Bierman PJ; Maness LJ; Vose JM; Armitage JO; Akhtari M
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):409-415.e1. PubMed ID: 25816932
[TBL] [Abstract][Full Text] [Related]
5. Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission.
Vose JM; Rizzo DJ; Tao-Wu J; Armitage JO; Bashey A; Burns LJ; Christiansen NP; Freytes CO; Gale RP; Gibson J; Giralt SA; Herzig RH; Lemaistre CF; McCarthy PL; Nimer SD; Petersen FB; Schenkein DP; Wiernik PH; Wiley JM; Loberiza FR; Lazarus HM; van Biesen K; Horowitz MM
Biol Blood Marrow Transplant; 2004 Feb; 10(2):116-27. PubMed ID: 14750077
[TBL] [Abstract][Full Text] [Related]
6. Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure.
Jiménez-Ubieto A; Grande C; Caballero D; Yáñez L; Novelli S; Hernández-Garcia MT; Manzanares M; Arranz R; Ferreiro JJ; Bobillo S; Mercadal S; Galeo A; López Jiménez J; Moraleda JM; Vallejo C; Albo C; Pérez E; Marrero C; Magnano L; Palomera L; Jarque I; Martínez-Sánchez P; Martín A; Coria E; López-Guillermo A; Salar A; Lahuerta JJ
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1631-1640. PubMed ID: 28533060
[TBL] [Abstract][Full Text] [Related]
7. High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis.
Strehl J; Mey U; Glasmacher A; Djulbegovic B; Mayr C; Gorschlüter M; Ziske C; Schmidt-Wolf IG
Haematologica; 2003 Nov; 88(11):1304-15. PubMed ID: 14607760
[TBL] [Abstract][Full Text] [Related]
8. Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway.
Smeland KB; Kiserud CE; Lauritzsen GF; Fagerli UM; Falk RS; Fluge Ø; Fosså A; Kolstad A; Loge JH; Maisenhölder M; Kvaløy S; Holte H
Haematologica; 2015 Jun; 100(6):e240-3. PubMed ID: 25682605
[No Abstract] [Full Text] [Related]
9. Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma.
Cremerius U; Fabry U; Wildberger JE; Zimny M; Reinartz P; Nowak B; Schaefer W; Buell U; Osieka R
Bone Marrow Transplant; 2002 Jul; 30(2):103-11. PubMed ID: 12132049
[TBL] [Abstract][Full Text] [Related]
10. High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study.
Schorb E; Fox CP; Fritsch K; Isbell L; Neubauer A; Tzalavras A; Witherall R; Choquet S; Kuittinen O; De-Silva D; Cwynarski K; Houillier C; Hoang-Xuan K; Touitou V; Cassoux N; Marolleau JP; Tamburini J; Houot R; Delwail V; Illerhaus G; Soussain C; Kasenda B
Bone Marrow Transplant; 2017 Aug; 52(8):1113-1119. PubMed ID: 28436974
[TBL] [Abstract][Full Text] [Related]
11. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma.
Cote GM; Hochberg EP; Muzikansky A; Hochberg FH; Drappatz J; McAfee SL; Batchelor TT; LaCasce AS; Fisher DC; Abramson JS; Armand P; Chen YB
Biol Blood Marrow Transplant; 2012 Jan; 18(1):76-83. PubMed ID: 21749848
[TBL] [Abstract][Full Text] [Related]
12. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.
Chen YB; Lane AA; Logan B; Zhu X; Akpek G; Aljurf M; Artz A; Bredeson CN; Cooke KR; Ho VT; Lazarus HM; Olsson R; Saber W; McCarthy P; Pasquini MC
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1046-1053. PubMed ID: 25687795
[TBL] [Abstract][Full Text] [Related]
13. Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma.
Dahi PB; Tamari R; Devlin SM; Maloy M; Bhatt V; Scordo M; Goldberg J; Zelenetz AD; Hamlin PA; Matasar MJ; Maragulia J; Giralt SA; Perales MA; Moskowitz CH; Sauter CS
Biol Blood Marrow Transplant; 2014 Dec; 20(12):2004-9. PubMed ID: 25175794
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older.
Gopal AK; Gooley TA; Golden JB; Maloney DG; Bensinger WI; Petersdorf SH; Appelbaum FR; Press OW
Bone Marrow Transplant; 2001 Mar; 27(6):593-9. PubMed ID: 11319588
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Total Body Irradiation (TBI) Conditioning with Non-TBI for Autologous Stem Cell Transplantation in Newly Diagnosed or Relapsed Mature T- and NK-Cell Non-Hodgkin Lymphoma.
Maeng CH; Ko YH; Lim DH; Kang ES; Choi JY; Kim WS; Kim SJ
Cancer Res Treat; 2017 Jan; 49(1):92-103. PubMed ID: 27188204
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma.
Laudi N; Arora M; Burns LJ; Miller JS; McGlave PB; Barker JN; Ramsay NK; Orchard PJ; Macmillan ML; Weisdorf DJ
Biol Blood Marrow Transplant; 2005 Feb; 11(2):129-35. PubMed ID: 15682074
[TBL] [Abstract][Full Text] [Related]
18. Second neoplasms following high-dose chemotherapy and autologous stem cell transplantation for malignant lymphomas: a report of six cases in a cohort of 171 patients from a single institution.
Oddou S; Vey N; Viens P; Bardou VJ; Faucher C; Stoppa AM; Chabannon C; Camerlo J; Bouabdallah R; Gastaut JA; Maraninchi D; Blaise D
Leuk Lymphoma; 1998 Sep; 31(1-2):187-94. PubMed ID: 9720728
[TBL] [Abstract][Full Text] [Related]
19. Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide.
Dean RM; Pohlman B; Sweetenham JW; Sobecks RM; Kalaycio ME; Smith SD; Copelan EA; Andresen S; Rybicki LA; Curtis J; Bolwell BJ
Br J Haematol; 2010 Jan; 148(2):226-34. PubMed ID: 19821828
[TBL] [Abstract][Full Text] [Related]
20. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry.
Mounier N; Canals C; Gisselbrecht C; Cornelissen J; Foa R; Conde E; Maertens J; Attal M; Rambaldi A; Crawley C; Luan JJ; Brune M; Wittnebel S; Cook G; van Imhoff GW; Pfreundschuh M; Sureda A;
Biol Blood Marrow Transplant; 2012 May; 18(5):788-93. PubMed ID: 22005647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]